Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.

For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com .

The statements herein include forward-looking statements. By their nature, forward-looking statements and forecasts involve risk and uncertainty. For a discussion of those risks and uncertainties please see the company's Annual Report/Form 20-F for 2006.

    References:

    (1) C Schulz, R Kahn, V Palazov, E Reyes, D Meulien, M Brecher, O

        Svensson, HM Andersson. "Efficacy of Once-Daily Extended Release

        Quetiapine Fumarate in Patients with Acute Schizophrenia." Annual

        Meeting of the American Psychiatric Association, 2007
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/2/2015)... , and DURHAM, N.C. , ... Inc. today announced its acquisition of assets related to ... PFE ) that had previously been obtained as ... Sciences also acquired all of Pfizer,s rights to the ... Icagen brand and will provide comprehensive services for ion ...
(Date:7/2/2015)... de 2015 BGI anunció hoy que su ... rendimiento en Hong Kong ha ... instalación de BGI en Hong Kong ... generación que recibe la certificación CAP en ... prácticas de laboratorio clínico. Junto con el exitoso proceso ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/9q4d5d/veterinary_ ) ... Animal Vaccines Market by Product, Diseases & Technology - ... The global animal vaccines market is poised ... in 2015, at a CAGR of 5.5% from 2015 ... are growing prevalence of animal diseases, increasing incidences of ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4BGI recibe la acreditación del College of American Pathologists (CAP) 2Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2
... today announced the launch of the CELLTRACKS® Circulating Melanoma ... convenient and reliable way to capture CMCs for research ... CMCs, the CELLTRACKS® CMC kit is designed to offer ... based on a specific protein or mutation. ...
... May 24, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical company ... announced that is has closed a $6 million investment ... based oncology focused venture capital fund.  Combined with the ... raised $43 million in the past year. The company ...
Cached Medicine Technology:Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 2Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 3TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 2TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 3TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd. 4
(Date:7/2/2015)... ... July 02, 2015 , ... ... providers, has been retained to lead a national chief executive officer recruitment ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:7/2/2015)... ... July 02, 2015 , ... After conducting a nationwide executive search ... Center in Yuma, Ariz., has hired Robert Trenschel, DO, as chief executive officer. ... Dr. Trenschel will assume his new duties at Yuma Regional Medical Center on July ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ... Gelatin Capsule manufacturers. The report is a valuable source of guidance and direction ... global and Chinese market for the Gelatin Capsule industry including capacity, production, production ...
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic ... their launch an intention to partner with companies that share a similar mission ... Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now ...
(Date:7/2/2015)... ... July 02, 2015 , ... Every year, DUI arrests and fatalities spike on the 4th of ... day of the year when it comes to being on the road. According to attorney ... Association reports that 40% of all highway deaths between 2007 and 2011 were caused by ...
Breaking Medicine News(10 mins):Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2
... , FRIDAY, June 24 (HealthDay News) -- Dieting ... young adulthood, a new study finds. Disordered eating includes ... meals and binge eating. Researchers analyzed ... for 10 years beginning in either early adolescence (about 13 ...
... the lung-damaging effects of traffic-related pollution (TRP) in children, ... Medicine of the University of Southern California (USC) in ... of the print edition of the American Thoracic Society,s ... . "This is the first study demonstrating that ...
... A group of 26 of the nation,s leaders in medicine, ... changes in the design, supervision and financing of U.S. hospital ... errors, and end dangerously long work hours for physicians ... the June 24 issue of the online journal Nature & ...
... with chronic obstructive pulmonary disease (COPD) who use inhaled ... have a 27 percent increased risk of bone fractures, ... subjects were mostly men age 60 and older, the ... effects on women with COPD, a group already at ...
... have found a likely explanation for the slow growth of ... tests on a new cell-based model of the tumor, they ... a growth-braking tumor-suppressor gene, in a process similar to that ... June 1 issue of Clinical Cancer Research , could ...
... SUWON, KOREAFormaldehyde is a major contaminant of indoor ... paper products, tobacco smoke, and other sources. Indoor ... contribute to allergies, asthma, headaches, and a condition ... widespread; a 2002 report from the World Health ...
Cached Medicine News:Health News:Extreme Dieting Often Lasts From Early Teens to Adulthood 2Health News:Exposure to parental stress increases pollution-related lung damage in children 2Health News:Experts seek reforms to prevent errors from medical resident fatigue, lack of supervision 2Health News:Experts seek reforms to prevent errors from medical resident fatigue, lack of supervision 3Health News:Experts seek reforms to prevent errors from medical resident fatigue, lack of supervision 4Health News:Study: Long-term inhaled corticosteroid use increases fracture risk in lung disease patients 2Health News:Slow growth of childhood brain tumors linked to genetic process seen in skin moles 2Health News:Study of phytoremediation benefits of 86 indoor plants published 2
... Digital Flexible Ureteroscope (DUR-D) incorporates many ... proven durable, market leading DUR® series ... first device utilizing Gyrus ACMIs proprietary, ... Metal Oxide Semi-Conductor (CMOS) distal sensor ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: